Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 10/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | ESRRA | P11474 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 2/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21147045 | 0.80 | CASR (0.34) | ESRRANOTUMPTGS1PTGS2 | |
| SCHEMBL20078232 | 0.68 | NPC1 (0.35) | MTORNOTUMRXRAGRIN1GRIN2B | |
| SCHEMBL24352271 | 0.68 | NOTUM (0.46) | GCGRMTORESRRANOTUMEGLN1 | |
| SCHEMBL14268227 | 0.67 | LMNA (0.38) | PTGS1PTGS2 | |
| SCHEMBL22902068 | 0.66 | NOTUM (0.50) | MTORESRRANOTUMEGLN1 | |
| SCHEMBL21721047 | 0.64 | EGLN1 (0.40) | GCGREGLN1 | |
| SCHEMBL24908596 | 0.64 | CASR (0.42) | GCGRNOTUMPTGS2NTRK1FLT3 | |
| SCHEMBL13528292 | 0.64 | CYP1A2 (0.40) | PTGS1PTGS2 | |
| SCHEMBL13657996 | 0.62 | GRM4 (0.40) | MTORNOTUM | |
| SCHEMBL15119356 | 0.62 | KDM5B (0.43) | MTORNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10906900-B2 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2021-02-02 | — | — | US | disclosed |
| US-20190211011-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10906900-B2 | Compounds for using in imaging and particularly for the diagnosis of neurodegenerative diseases | PSEN2, CLN6, MAPT | GCGR 2769/4885MTOR 1290/4885ESRRA 3678/4885 |
| US-20190211011-A1 | COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES | PSEN2, SNCA, MAPT | GCGR 3075/4885MTOR 1550/4885ESRRA 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.